keyword
https://read.qxmd.com/read/38530527/influence-of-neoadjuvant-immunotherapy-chemotherapy-on-perioperative-outcomes-in-locally-advanced-esophageal-adenocarcinoma
#1
JOURNAL ARTICLE
Yehonatan Nevo, James Tankel, Hedi Zhao, Jaime Ramirez, Jonathan Cools-Lartigue, Carmen Muller, Thierry Alcindor, Lorenzo Ferri
BACKGROUND: This study evaluated the perioperative outcomes for patients who had locally advanced esophageal adenocarcinoma (EAC) treated with neoadjuvant immunotherapy (IO) and chemotherapy versus a matched cohort of patients who received neoadjuvant chemotherapy (NAC) alone. METHODS: A single-center non-randomized phase 2 trial was undertaken with locally advanced (cT3-4 and/or N+) EAC, and 49 patients completed neoadjuvant avelumab + docetaxel, cisplatin, 5FU (DCF) and esophagectomy between February 2018 and February 2020...
March 26, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38525708/infusion-related-reactions-subsequent-to-avelumab-durvalumab-and-atezolizumab-administration-a-retrospective-observational-study
#2
JOURNAL ARTICLE
Keiko Hata, Keina Nakamura, Shinichiro Maeda, Makiko Maeda, Yasushi Fujio, Sachiko Hirobe
BACKGROUND: Avelumab, durvalumab, and atezolizumab are anti-programmed death-ligand 1 (PD-L1) antibodies approved for clinical application in Japan. Despite targeting the same molecule, avelumab elicits a different frequency of infusion-related reactions (IRRs) compared with durvalumab and atezolizumab, leading to differences in premedication recommendations. This study aimed to collect information to verify the relationship during IRRs and the characteristics of antibody molecules, by investigating the frequency of IRRs caused by three types of antibodies and the actual status of prophylactic measures...
February 23, 2024: Clinics and Practice
https://read.qxmd.com/read/38522382/a-multiplex-uplc-ms-ms-method-for-the-quantification-of-three-pd-l1-checkpoint-inhibitors-atezolizumab-avelumab-and-durvalumab-in-human-serum
#3
JOURNAL ARTICLE
Pauline L M Buitelaar, Karen A M de Jong, Leon Aardenburg, Michiel S van der Heijden, Alwin D R Huitema, Jos H Beijnen, Hilde Rosing
BACKGROUND AND AIM: To support pharmacokinetic studies, a multiplex UPLC-MS/MS assay was developed and validated to quantify PD-L1 checkpoint inhibitors atezolizumab, avelumab, and durvalumab in serum. METHODS: A bottom-up sample pre-treatment procedure was developed to determine atezolizumab, avelumab, and durvalumab in serum. This procedure consisted of (1) precipitation of the monoclonal antibody with ammonium sulfate, (2) reduction with dithiothreitol, (3) denaturation with methanol, and (4) tryptic digestion of the protein...
March 16, 2024: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/38521617/avelumab-plus-intermittent-axitinib-in-previously-untreated-patients-with-metastatic-renal-cell-carcinoma-the-tide-a-phase-2-study
#4
JOURNAL ARTICLE
Roberto Iacovelli, Chiara Ciccarese, Sebastiano Buti, Paolo Andrea Zucali, Emanuela Fantinel, Davide Bimbatti, Elena Verzoni, Caterina Accettura, Lucia Bonomi, Consuelo Buttigliero, Giuseppe Fornarini, Stefania Pipitone, Francesco Atzori, Cristina Masini, Francesco Massari, Francesca Primi, Alessandro Strusi, Giulia Claire Giudice, Matteo Perrino, Marco Maruzzo, Michele Milella, Diana Giannarelli, Matteo Brunelli, Giuseppe Procopio, Giampaolo Tortora
BACKGROUND: Combinations of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitor (ICI) against PD1/PD-L1 are the standard first-line therapy for patients with metastatic renal cell carcinoma (mRCC), irrespective of the prognostic class. OBJECTIVE: To investigate the feasibility and safety of withdrawing VEGFR-TKI but continuing anti-PD1/PD-L1 in patients who achieve a response to their combination...
March 22, 2024: European Urology
https://read.qxmd.com/read/38521009/the-more-the-merrier-evidence-and-efficacy-of-immune-checkpoint-and-tyrosine-kinase-inhibitor-combinations-in-advanced-solid-cancers
#5
REVIEW
Angelika M Starzer, Ladislaia Wolff, Petar Popov, Barbara Kiesewetter, Matthias Preusser, Anna S Berghoff
Immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) have gained therapeutical significance in cancer therapy over the last years. Due to the high efficacy of each substance group, additive or complementary effects are considered, and combinations are the subject of multiple prospective trials in different tumor entities. The majority of available data results from clinical phase I and II trials. Although regarded as well-tolerated therapies ICI-TKI combinations have higher toxicities compared to monotherapies of one of the substance classes and some combinations were shown to be excessively toxic leading to discontinuation of trials...
March 15, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38520533/early-microvascular-coronary-endothelial-dysfunction-precedes-pembrolizumab-induced-cardiotoxicity-preventive-role-of-high-dose-of-atorvastatin
#6
JOURNAL ARTICLE
Panagiotis Efentakis, Angeliki Choustoulaki, Grzegorz Kwiatkowski, Aimilia Varela, Ioannis V Kostopoulos, George Tsekenis, Ioannis Ntanasis-Stathopoulos, Anastasios Georgoulis, Constantinos E Vorgias, Harikleia Gakiopoulou, Alexandros Briasoulis, Constantinos H Davos, Nikolaos Kostomitsopoulos, Ourania Tsitsilonis, Meletios Athanasios Dimopoulos, Evangelos Terpos, Stefan Chłopicki, Maria Gavriatopoulou, Ioanna Andreadou
Immune checkpoint inhibitors (ICIs) exhibit remarkable antitumor activity and immune-related cardiotoxicity of unknown pathomechanism. The aim of the study was to investigate the ICI class-dependent cardiotoxicity in vitro and pembrolizumab's (Pem's) cardiotoxicity in vivo, seeking for translational prevention means. Cytotoxicity was investigated in primary cardiomyocytes and splenocytes, incubated with ipilimumab, Pem and avelumab. Pem's cross-reactivity was assessed by circular dichroism (CD) on biotechnologically produced human and murine PD-1 and in silico...
March 23, 2024: Basic Research in Cardiology
https://read.qxmd.com/read/38518592/immune-related-adverse-events-associated-with-first-line-immune-checkpoint-inhibitors-for-metastatic-renal-cell-carcinoma-a-systematic-review-and-network-meta-analysis
#7
REVIEW
Shan Wang, Hongwei Lv, Jing Yu, Miao Chen
BACKGROUND: In the realm of metastatic renal cell carcinoma (mRCC), the introduction of immune checkpoint inhibitors (ICIs) has revolutionized treatment paradigms. Despite their effectiveness, the comprehensive safety profile of these therapies remains inadequately explored. This network meta-analysis aims to comparing the safety profiles of ICI-based treatments in mRCC, offering vital insights that could lead to the optimization of treatment strategies and improvement of patient care...
March 21, 2024: International Immunopharmacology
https://read.qxmd.com/read/38518549/phase-ii-trial-of-domatinostat-4sc-202-in-combination-with-avelumab-in-patients-with-previously-treated-advanced-mismatch-repair-proficient-oesophagogastric-and-colorectal-adenocarcinoma-emerge
#8
JOURNAL ARTICLE
E Cartwright, S Slater, C Saffery, A Tran, F Turkes, G Smith, M Aresu, D Kohoutova, M Terlizzo, O Zhitkov, I Rana, E W Johnston, I Sanna, E Smyth, W Mansoor, C Fribbens, S Rao, I Chau, N Starling, D Cunningham
BACKGROUND: Most oesophagogastric adenocarcinomas (OGAs) and colorectal cancers (CRCs) are mismatch repair proficient (MMRp), responding poorly to immune checkpoint inhibition. We evaluated the safety and efficacy of domatinostat (histone deacetylase inhibitor) plus avelumab (anti-PD-L1 antibody) in patients with previously treated inoperable, advanced/metastatic MMRp OGA and CRC. PATIENTS AND METHODS: Eligible patients were evaluated in a multicentre, open-label dose escalation/dose expansion phase II trial...
March 21, 2024: ESMO Open
https://read.qxmd.com/read/38513188/pace-a-randomized-phase-ii-study-of-fulvestrant-palbociclib-and-avelumab-after-progression-on-cyclin-dependent-kinase-4-6-inhibitor-and-aromatase-inhibitor-for-hormone-receptor-positive-human-epidermal-growth-factor-receptor-negative-metastatic-breast-cancer
#9
JOURNAL ARTICLE
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara Abdou, Elizabeth C Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Natalie Sinclair, Meredith Faggen, Caroline C Block, Naomi Ko, Ann H Partridge, Wendy Y Chen, Michelle DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M Tolaney
PURPOSE: Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), but it is not known if patients might derive benefit from continuation of CDK4/6i with endocrine therapy beyond initial tumor progression or if the addition of checkpoint inhibitor therapy has value in this setting. METHODS: The randomized multicenter phase II PACE trial enrolled patients with hormone receptor-positive/HER2- MBC whose disease had progressed on previous CDK4/6i and aromatase inhibitor (AI) therapy...
March 21, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38501128/guillain-barr%C3%A3-syndrome-and-checkpoint-inhibitor-therapy-insights-from-pharmacovigilance-data
#10
REVIEW
Andre Abrahao, Pedro Henrique de Magalhães Tenório, Mariana Rodrigues, Monica Mello, Osvaldo José Moreira Nascimento
Background There are increasing reports of cases of Guillain-Barré syndrome (GBS), as an adverse event of an immune checkpoint inhibitor (ICI) but postmarket data on the incidence of this remains scarce. This study sought to conduct a comprehensive review of GBS events arising as a secondary outcome of ICI treatments in real-world patients, using the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods Data covering the period from the third quarter of 2003 to the second quarter of 2023 were extracted from the FAERS database...
2024: BMJ neurology open
https://read.qxmd.com/read/38496061/programmed-death-1-inhibitor-immunotherapy-induced-symptomatic-toxic-thyroid-nodule
#11
Owen Cole, Prahasith Kamani, Vikash Kumar, Jacob Warman
Immune checkpoint inhibitors, specifically programmed death-ligand 1 (PD-LI) inhibitors, are immune modifying medications that increasingly treat specific types of cancer. They are known to cause many side effects, including thyroid-related side effects. The use of PD-L1 inhibitors can cause hypothyroidism most commonly, while hyperthyroidism occurs less frequently. This case report describes a patient who developed a toxic thyroid nodule while taking the PD-L1 inhibitor, avelumab, for the treatment of Merkel cell carcinoma...
February 2024: Curēus
https://read.qxmd.com/read/38459780/a-phase-1-study-of-interleukin-15-in-combination-with-avelumab-in-relapsed-or-refractory-t-cell-lymphoma
#12
JOURNAL ARTICLE
Max J Gordon, Sigrid Dubois, Bonita Bryant, Samuel Ng, Kevin Conlon, Milos D Miljkovic, Thomas Waldmann, Mark Roschewski
No abstract text is available yet for this article.
March 9, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38447555/real-world-evidence-of-tumor-and-patient-characteristics-and-survival-with-avelumab-maintenance-after-chemotherapy-for-advanced-and-metastatic-urothelial-carcinoma
#13
JOURNAL ARTICLE
Séverine Banek, Mike Wenzel, Benedikt Lauer, Quynh Chi Le, Benedikt Hoeh, Florestan Koll, Cristina Cano Garcia, Clara Humke, Jens Köllermann, Felix K H Chun, Marina Kosiba, Luis A Kluth
PURPOSE: Despite the prospective randomized controlled JAVELIN Bladder 100 trial, no real-world evidence exists regarding tumor characteristics, adverse events (AE) and survival of avelumab maintenance (AVM) treated patients with partial/complete response or stable disease after previous platinum-based chemotherapy for advanced/metastatic urothelial carcinoma (mUC). METHODS: We relied on our institutional database to identify mUC patients who received AVM between 01/2021-12/2023...
March 6, 2024: Urologia Internationalis
https://read.qxmd.com/read/38440705/avelumab-plus-axitinib-for-translocation-renal-cell-carcinoma-a-case-series-and-literature-review
#14
Kenta Takahashi, Renpei Kato, Daiki Ikarashi, Tomohiko Matsuura, Shigekatsu Maekawa, Mitsugu Kanehira, Ryo Takata, Jun Sugimura, Takaya Abe, Wataru Obara
INTRODUCTION: Patients with translocation renal cell carcinoma (tRCC) have a poor prognosis without standardized treatment. CASE PRESENTATION: The first case was of a 72-year-old woman who underwent robot-assisted partial nephrectomy for a left renal tumor and was pathologically diagnosed with tRCC. Recurrence was observed in the left retroperitoneal soft tissue. After treatment with avelumab-axitinib, continued progression-free survival was confirmed at the 90-week follow-up...
March 2024: IJU case reports
https://read.qxmd.com/read/38440703/successful-treatment-with-enfortumab-vedotin-of-metastatic-signet%C3%A2-ring-cell-cancer-expressing-nectin-4-and-originating-from-the%C3%A2-bladder
#15
Maria Aoki, Taku Naiki, Aya Naiki-Ito, Toshiharu Morikawa, Nayuka Matsuyama, Koei Torii, Taiki Kato, Tetsuji Maruyama, Shingo Inaguma, Takahiro Yasui
INTRODUCTION: As an aggressive adenocarcinoma phenotype, primary signet ring cell carcinoma of the urinary bladder is an extremely rare variant. The prognosis of metastatic signet ring cell carcinoma of the urinary bladder is extremely poor and the clinical course for its specific pathogenesis remains unelucidated. CASE PRESENTATION: A 64-year-old Japanese male patient was diagnosed with invasive urothelial carcinoma with glandular differentiation of a signet ring cell-type with pT4aN0M0, and he was eventually diagnosed with metastatic signet ring cell carcinoma of the urinary bladder...
March 2024: IJU case reports
https://read.qxmd.com/read/38440696/a-case-of-complete-response-to-avelumab-plus-axitinib-combination-therapy-for-metastatic-clear-cell-renal-cell-carcinoma-in-a-kidney-undergoing-dialysis
#16
Ei Shiomi, Yuta Goto, Mizuki Hisano, Rento Ito, Makoto Moriwaka, Daiki Ikarashi, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira, Takashi Ujiie, Wataru Obara
INTRODUCTION: Combination therapies of immune checkpoint and tyrosine kinase inhibitors for end-stage kidney disease and patients on hemodialysis need careful consideration as few case reports provide suitable management decisions. CASE PRESENTATION: A 70-year-old man who had undergone hemodialysis for 6 years due to nephrosclerosis. Avelumab plus axitinib combination therapy was performed for repeated lung metastasis, and a complete response was achieved without major side effects...
March 2024: IJU case reports
https://read.qxmd.com/read/38439727/merkel-cell-carcinoma-of-unknown-primary-origin
#17
JOURNAL ARTICLE
Helena Francetić, Luka Simetić, Čedna Tomasović Lončarić, Daška Štulhofer Buzina, Romana Čeović
Merkel cell carcinoma (MCC) is a rare and highly aggressive primary cutaneous neuroendocrine carcinoma most often occurring in the elderly. Risk factors include chronic sun exposure and immunosuppression (1). MCC is associated with frequent recurrences and a high metastatic potential and mortality rate (1). It is the second most common cause of skin-cancer-related death after melanoma. At primary diagnosis with an apparent cutaneous tumor, loco-regional metastases are present in up to 30% of patients, and 6-12% have distant metastatic disease (2-3)...
December 2023: Acta Dermatovenerologica Croatica: ADC
https://read.qxmd.com/read/38433375/safety-and-effectiveness-of-avelumab-in-patients-with-merkel-cell-carcinoma-in-general-clinical-practice-in-japan-post-marketing-surveillance
#18
JOURNAL ARTICLE
Hisashi Uhara, Yoshio Kiyohara, Taiki Isei, Kotaro Nagase, Anzu Kambe, Masashi Sato, Yutaro Tanaka, Naoya Yamazaki
Avelumab, a programmed cell death ligand 1 blocking antibody, was approved for its first indication in Japan in September 2017 to treat unresectable Merkel cell carcinoma (MCC). Given that the pivotal JAVELIN Merkel 200 study only included a few Japanese patients, this post-marketing surveillance (PMS) evaluated the safety and effectiveness outcomes of patients with MCC who received avelumab in general clinical practice in Japan. This prospective, non-comparative, multicenter PMS included data from all patients with unresectable MCC who received avelumab between November 22, 2017 (avelumab launch date) and October 31, 2019...
March 3, 2024: Journal of Dermatology
https://read.qxmd.com/read/38423921/avelumab-to-treat-merkel-cell-carcinoma-real-life-experience-in-a-dedicated-oncology-center
#19
E Ríos-Viñuela, M García-Vázquez, M J Juan, E Nagore, C Requena, O Sanmartín, B Llombart
The arrival of immunotherapy has revolutioned the management of patients with metastatic Merkel cell carcinoma (MCC). We conducted an observational, retrospective study of 14 cases treated with avelumab. The response rate was 57%: complete response was reached in 29% of patients, and partial responses in 29%. The drug proved effective in 83% (5/6) of the patients with a single metastatic site. However, the disease progressed in 75% (3/4) of the patients with bone metastases. PD1-L expression, MCC polyomavirus (MCPyV) positivity, and an impaired neutrophil-to-lypmhocyte ratio (NLR) could not be associated with responses to the therapy...
February 2, 2024: Actas Dermo-sifiliográficas
https://read.qxmd.com/read/38423657/comparison-of-oncological-outcomes-of-pembrolizumab-as-second-line-therapy-and-maintenance-avelumab-therapy-in-advanced-urothelial-carcinoma-after-platinum-based-chemotherapy
#20
JOURNAL ARTICLE
Tetsuya Shindo, Kohei Hashimoto, Atsushi Takahashi, Shintaro Miyamoto, Yasuharu Kunishima, Shunsuke Sato, Fumimasa Fukuta, Yoshiki Hiyama, Akio Takayanagi, Ryuichi Kato, Atsushi Wanifuchi, Yohei Ueki, Manabu Okada, Hideki Adachi, K O Kobayashi, Toshiaki Tanaka, Naoya Masumori
BACKGROUND/AIM: Sequential therapy using chemotherapy and subsequent immune checkpoint inhibitor (ICI) treatment prolongs the survival of patients with advanced urothelial carcinoma (UC). However, no comparison data for oncological outcome between pembrolizumab and avelumab has been reported. Thus, we compared oncological outcomes between pembrolizumab as second-line therapy and maintenance avelumab therapy in patients with advanced UC. PATIENTS AND METHODS: We retrospectively evaluated patients with advanced UC treated with pembrolizumab or avelumab between January 2018 and February 2023...
March 2024: Anticancer Research
keyword
keyword
69709
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.